Aligning a Drug's Price to Its Benefit: A 12-Month Review and Forecast of Value-Based Pricing in the U.S.

Can a gene therapy really be worth $2 million? Then what happens when there are 20 of them? ICER’s Dr. Steve Pearson will take a look at the growing influence of value-based price benchmarking in the US, introduce new tools to inform pricing and coverage decisions, and preview the year ahead.


Steven D. Pearson MD, MSc, President, Institute for Clinical Economic Review (ICER)


Tuesday, March 3, 2:25 pm to 3:25 pm - General Session